BRAF and melanoma: Melanoma frequently develops resistance to BRAF/MEK-targeted therapy and immune checkpoint blockade (ICB), often through therapy-driven tumor state transitions that include immune exclusion, transcriptional plasticity, and microenvironmental remodeling.